These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34253805)

  • 41. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
    Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
    BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
    Shibutani M; En W; Okazaki Y; Kashiwagi S; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
    Anticancer Res; 2021 Dec; 41(12):6211-6216. PubMed ID: 34848475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
    Martínez-Lago N; Chucla TC; De Castro BA; Ponte RV; Rendo CR; Rodriguez MIG; Diaz SS; Suarez BG; de la Cámara Gomez J; Fernández FB; Salvador MM; Lopez MR
    Sci Rep; 2022 Aug; 12(1):14612. PubMed ID: 36028552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
    Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
    Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
    Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
    Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil.
    Giuliani J; Bonetti A
    Anticancer Res; 2019 Jul; 39(7):3967-3969. PubMed ID: 31262929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey.
    Özet A; Dane F; Aykan NF; Yalçın Ş; Evrensel T; Özkan M; Karabulut B; Ormeci MN; Atasev O; Vidot L; Çiçin İ
    Future Oncol; 2022 Sep; 18(29):3267-3276. PubMed ID: 36040321
    [No Abstract]   [Full Text] [Related]  

  • 48. Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status.
    Carriles C; Jimenez-Fonseca P; Sánchez-Cánovas M; Pimentel P; Carmona-Bayonas A; García T; Carbajales-Álvarez M; Lozano-Blázquez A
    Clin Transl Oncol; 2019 Dec; 21(12):1781-1785. PubMed ID: 31209792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
    Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I
    Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
    Giuliani J; Fiorica F; Ponturo G; Azzurro M; Ruzzenente A; Bonetti A
    J Oncol Pharm Pract; 2021 Jun; 27(4):974-977. PubMed ID: 33541208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
    Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada.
    Samawi HH; Brezden-Masley C; Afzal AR; Cheung WY; Dolley A
    Curr Oncol; 2019 Oct; 26(5):319-329. PubMed ID: 31708650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrated safety summary for trifluridine/tipiracil (TAS-102).
    Falcone A; Ohtsu A; Van Cutsem E; Mayer RJ; Buscaglia M; Bendell JC; Kopetz S; Bebeau P; Yoshino T
    Anticancer Drugs; 2018 Jan; 29(1):89-96. PubMed ID: 29176395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
    Yoshino T; Van Cutsem E; Li J; Shen L; Kim TW; Sriuranpong V; Xuereb L; Aubel P; Fougeray R; Cattan V; Amellal N; Ohtsu A; Mayer RJ
    ESMO Open; 2022 Jun; 7(3):100511. PubMed ID: 35688062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
    Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
    Yoshino T; Cleary JM; Van Cutsem E; Mayer RJ; Ohtsu A; Shinozaki E; Falcone A; Yamazaki K; Nishina T; Garcia-Carbonero R; Komatsu Y; Baba H; Argilés G; Tsuji A; Sobrero A; Yamaguchi K; Peeters M; Muro K; Zaniboni A; Sugimoto N; Shimada Y; Tsuji Y; Hochster HS; Moriwaki T; Tran B; Esaki T; Hamada C; Tanase T; Benedetti F; Makris L; Yamashita F; Lenz HJ
    Ann Oncol; 2020 Jan; 31(1):88-95. PubMed ID: 31912801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trifluridine/tipiracil in the treatment of gastric cancer.
    Fostea RM; Arkenau HT
    Future Oncol; 2022 Apr; 18(12):1511-1517. PubMed ID: 35081748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
    Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
    Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.
    Burness CB; Duggan ST
    Drugs; 2016 Sep; 76(14):1393-402. PubMed ID: 27568360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.
    Van Cutsem E; Falcone A; Garcia-Carbonero R; Komatsu Y; Pastorino A; Peeters M; Shimada Y; Yamazaki K; Yoshino T; Zaniboni A; Amellal N; Kanehisa A; Winkler R; Makris L; Mayer RJ; Ohtsu A; Tabernero J
    ESMO Open; 2017; 2(5):e000261. PubMed ID: 29215098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.